Development of an antibody cocktail for treatment of Sudan virus infection
Domain:
healthcareCreator:
AndJefRamAna
Publisher:
Nat
Host:
Significance
Ebolaviruses pose a significant threat to the global community, particularly in areas of equatorial and West Africa. While Ebola virus has caused the greatest number of human cases, Sudan virus is responsible for numerous outbreaks with equally lethal consequences. Antibody-based immunotherapies against ebolaviruses have gained prominence in recent years, resulting in the development of several Ebola virus-specific antibody cocktails, yet no Sudan virus-specific cocktails exist. In collaboration with industry partners, we generated a library of human chimeric monoclonal antibodies (mAbs) specific for the glycoprotein of Sudan virus. Through a series of in vitro assays and rodent efficacy studies, we down-selected a lead mAb cocktail that demonstrated protective efficacy in a nonhuman primate model of Sudan virus infection.
Similar
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceA Serological Survey of Akabane Virus Infection in Cattle in SudanCombination of two antibody fragments F(ab')(2)/Fab: an alternative for scorpion envenoming treatment.Diagnosis, treatment and prevention of hepatitis B virus infection in Kilifi, KenyaHigh Seroprevalence of Dengue Virus Infection in Sudan: Systematic Review and Meta-AnalysisAntibody response following Ebola infection.